Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: Increased efficacy and reduced toxicity when given subcutaneously

British Journal of Cancer

Volumn 74, Issue 7, 1996, Pages 1132-1136

  Honkoop, A H ^a   Hoekman, K ^a   Wagstaff, J ^a   Van Groeningen, C J ^a   Vermorken, J B ^a   Boven, E ^a   Pinedo, H M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Chemotherapy; Granulocyte macrophage colony stimulating factor; Route of administration

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE TRANSFUSION; VEIN THROMBOSIS; VOMITING;

EID: 0029780533     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.502     Document Type: Article

References (32)

1. ANTIN SJ, SMITH BR, HOLMES W AND ROSENTHAL DS. (1988). Phase I/II study of recombinant human granulocyte - macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood, 72, 705 - 713.
2. ANTMAN K, GRIFFIN J, ELIAS A, SOCINKSI MA, RYAN L, CANNISTRA SA, OETTE D, WHITLEY M, FREI III E AND SCHNIPPER LE. (1988). Effects of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N. Engl. J. Med., 319, 593 - 598.
3. ARDIZZONI A, VENTURINI M, SERTOLI MR, GIANNESSI PG, BREMA F, DANOVA M, TESTORE F, MARIANA GL, PENNUCCI MC, OUEIROLO P, SILVESTRO S, BRUZZI P, LIONETTO R, LATINI F AND ROSSO R. (1994). Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. Br. J. Cancer, 69, 385 391.
4. B+ISHOP MR, ANDERSON JR, JACKSON JD, BIERMAN PJ, REED EC, VOSE JM, ARMITAGE JO, WARKENTIN PI AND KESINGER A. (1994). High dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte macrophage colony-stimulating factor on the autograft. Blood, 83, 610 616.
5. BRANDT SJ, PETERS WP, ATWATER SK, KURTZENBERG J, BOROWITZ MJ, JONES RB, SHPALL EJ, BAST RC, GILBERT CJ AND OETTE DH. (1988). Effect of recombinant granulocyte macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med., 318, 869 876.
6. CEBON J, DEMPSEY P, FOX RM, KANNOURAKIS G, BONNEM E, BURGESS AW AND MORSTYN G. (1988). Pharmacokinetics of human granulocyte-macrophage-stimulating factor (hGM-CSF) using a sensitive immunoassay. Blood, 72, 1340 1347.
7. CEBON J, LIESCHKE GJ, BURY RW AND MORSTYN G. (1992). The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study. Br. J. Haematol., 80, 144 150.
8. DE VRIES EGE, WILLEMSE PHB, BIESMA B, STERN AC, LIMBURG PC AND VELEENGA E. (1991). Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet, 338, 517 518.
9. EDMONSON JH, LONG HJ, JEFFRIES JA, BUCKNER JC, COLONOTERO G AND FITCH TR. (1989). Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF: apparent dose and schedule dependency. J. Natl Cancer Inst., 81, 1510 1512.
10. GERHARTZ HH, ENGELHART M, MEUSERS P, BRITTINGER G, WILMANNS W, SCHLIMOK G, MUELLER P, HUHN D, MUSCH R AND SIEGERT W. (1993). Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte macrophage colony-stimulating factor as adjunct to induction treatment of high-grade non-Hodgkin's lymphomas. Blood, 82, 2329 2339.
11. GIANNI AM, SIENA S, BREGNI M, TARELLA C, STERN AC, PILERI A AND BONADONNA G. (1989). Granulocyte macrophage colony-stimulating factor to harvest circulating haemapoietic stem cells for autotransplantation. Lancet, 2, 580 585.
12. GORDON B, SPADINGER A, HODGES E, RUBY E, STANLY R AND COCCIA P. (1994). Effect of granulocyte macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J. Clin. Oncol., 12, 1917 1922.
13. GROOPMAN JE, MITSUYASU RT, DELEO MJ, OETTE DH AND GOLDE DW, (1987). Effect of recombinant human granulocyte macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N. Engl. J. Med., 317, 593 598.
14. HARMENBERG J. HOGLUND M AND HELLSTROM-LINDBERG E. (1994). G- and GM-CSF in oncology and oncological haematology. Eur. J. Haematol. (suppl.) 55, 1 28.
15. HILL RJ, WARREN MK AND LEVIN J. (1990). Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. J. Clin. Invest., 85, 1242 1247.
16. HOEKMAN K, WAGSTAFF J, VAN GROENINGEN CJ, VERMORKEN JB, BOVEN E AND PINEDO HM. (1991a). Effects of recombinant human granulocyte macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high dose chemotherapy in patients with advanced breast cancer. J. Natl Cancer Inst., 83, 1546 1553.
17. HOEKMAN K, VON BLOMBERG-VAN DER FLIER BME, WAGSTAFF J, DREXHAGE HA AND PINEDO HM. (1991b). Reversible thyroid dysfunction during treatment with GM-CSF. Lancet, 338, 541 542.
18. KAPLAN LD, KAHN JO, CROWE S, NORDTFELT D, NEVILEE P, GROSSBERG H, ABRAMS DI, TRACEY J, MILLS J AND VOLBERDING PA. (1991). Clinical and virologic effects of recombinant human granulocyte macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus associated non-Hodgkin's lymphoma: results of a randomized trial. J. Clin. Oncol., 9, 929 940.
19. LIESCHKE GJ, MAHER D, CEBON J, O'CONNER M, GREEN M, SHERIDAN W, BOYD A, RALLINGS M, BONNEM E, METCALF D, BURGESS AW, McGRATH K, FOX RM AND MORSTYN G. (1989). Bacterially synthesized recombinant human granulocyte colony-stimulating factor in patients with advanced malignancy. Ann. Intern. Med., 110, 357 364.
20. LIESCHKE GJ, MAHER D, O'CONNOR M, GREEN M, SHERIDAN W, RALLINGS M, BONNEM E, BURGESS AW, MCGRATH K, FOX RM AND MORSTYN G. (1990). Phase I study of intravenously administered bacterially synthesized granulocyte macrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res., 50, 606 614.
21. LOCKHART PB AND SONIS ST. (1979). Relationship of oral complications to peripheral blood leucocyte and platelet counts in patients receiving cancer chemotherapy. Oral Surg., 48, 21 28.
22. NAWROTH PP AND STERN DM. (1986). Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med., 163, 740 745.
23. NEMUNAITIS J, RABINOWE SN, SINGER JW, BIERMAN PJ, VOSE JM, FREEDMAN AS, ONETTO N, GILLIS S, OETTE D, GOLD M, BUCKNER D, HANSEN JA, RITZ J, APPELBAUM FR, ARMITAGE JO AND NADLER LM. (1991). Recombinant granulocyte-macrophage stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N. Engl. J. Med., 324, 1773 1778.
24. O'SHAUGNESSY JA, DENICOFF AM, VENZON DJ, DANFORTH D, PIERCE LJ, FRAME JN, BASTIAN A, GHOSH B, GOLDSPIEL B, MILLER E, DORR FA, KEEGAN P, BENBARUCH N, MROSE H, NOONE M AND COWAN KH. (1994). A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escheriehia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients. Ann. Oncol., 5, 709 716.
25. RUEF C AND COLEMAN DL. (1990). Granulocyte macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev. Infect. Dis., 12, 41 62.
26. RUSTEN LS AND JACOBSEN SE. (1995). Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood, 85, 989 996.
27. 1 and tumor necrosis factor by human nuclear cells stimulated with granulocyte macrophage colony-stimulating factor. Blood, 72, 1368 1374.
28. STEHLE B, WEIS C, HO AD AND HUNSTEIN W. (1990). Serum levels of tumor necrosis factor α in patients treated with granulocyte-macrophage colony-stimulating factor. Blood, 75, 1895 1896.
29. STEWARD WP, SCARFFE JH, AUSTIN R, BONNEM E, THATCHER N, MORGENSTERN G AND CROWTHER D. (1989). Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) given as daily short infusion a phase I dose-toxicity study. Br. J. Cancer, 59, 142 145.
30. SUDERLAND M, ABELOFF M AND NEIDHART J. (1991). Continuous GM-CSF failed to ameliorate neutropenia and worsened thrombocytopenia in a dose-intensive regimen for breast cancer patients (abstract). Breast Cancer Res. Treat., 19, 158.
31. VADHAN-RAJ S, KEATING M, LEMAISTRE A, HITTELMAN WN, McGREDIE K, TRUJILLO JM, BOXMEYFR HE, HENNEY C AND GUTTERMAN JU. (1987). Effects of recombinant human granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N. Engl. J. Med., 317, 1545 1552.
32. VADHAN-RAJ S, BEUSCHER S, HORWITZ LJ, LEMAISTRE A, KEATING M, WALTERS W, VENTURA C, HITTELMAN W, BROXMEYER HE AND GUTTERMAN JU. (1988). Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. Blood, 72, 134 141.